Assessment of Cell-mediated Immunity to Trichophyton Antigen in Patients with Dermatophytosis: A Case-control Study

Abstract

Introduction: Dermatophytosis are presenting for longer durations and at atypical sites and are quite persistent. If changes in the Cell-Mediated Immunity (CMI) will be studied then it will help to set treatment guidelines for the management of dermatophytosis to certain extent considering the current changes in the resistance to dermatophytosis. There is paucity in literature regarding the CMI to Trichophyton antigen in dermatophytosis patients in the geographical region of Vidarbha, Maharashtra, India. Aim: To assess the CMI to intradermal Trichophyton antigen in dermatophytosis patients and to study its adverse reaction in these patients. Materials and Methods: The present prospective crosssectional case-control study will be conducted on patients of dermatophytosis attending skin Outpatient Department (OPD) in Acharya Vinoba Bhave Rural Hospital(AVBRH), Sawangi, Wardha, Maharashtra, India, during January 2022 to January 2023 (13 months). Patients will be enrolled following fulfillment of study’s eligibility criteria. Clearance has been acquired from the Institutional Ethical Committee (IEC). Participants will be required to sign a written informed consent form in their native language. A detailed history will be collected and cutaneous examination will be done before conducting the study. The area for intradermal injection will be marked. For the study 0.1 mL, Intradermal Trichophyton antigen will be injected in the patient’s forearm. Patient will be called after 48 hours to check for the CMI response (delayed response).